Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018)

Autor: Xavier Pivot, Anne Doly, Julien Manson, L. Samelson, Paul Cottu, Olivier Aujoulat, Hugues Barletta, Nassera Chalabi, Bruno Coudert, David Pérol

Publikováno v: European Journal of Cancer
European Journal of Cancer, 2020, 141, pp.209-217. ⟨10.1016/j.ejca.2020.10.012⟩
European Journal of Cancer, Elsevier, 2020, 141, pp.209-217. ⟨10.1016/j.ejca.2020.10.012⟩

International audience; Background: There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project using hospital data to analyse evolution in the therapeuti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce1dd8c8aad413817f10cd639114d74c
https://hal.science/hal-03493774

The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France

Autor: Bruno Coudert, O Aujoulat, D Azria, J Pinguet, A Doly, J Manson, R Montastier, H Barletta, X Pivot, N Grandfils, D Perol, V. Machuron, L. Samelson, B Tehard, Paul-Henri Cottu

Publikováno v: Value in Health. 20:A743

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7038539e89df93feee05af29f155294
https://doi.org/10.1016/j.jval.2017.08.2058

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin

Autor: Philippe Wolf, Didier Samuel, Karim Boudjema, Christophe Duvoux, Lionel Rostaing, Olivier Boillot, Claire Vanlemmens, Yvon Calmus, Martine Neau-Cransac, Jean Gugenheim, Danielle Botta-Fridlund, Georges Philippe Pageaux, François Durand, Olivier Chazouillères, Sébastien Dharancy, L. Samelson

Publikováno v: Journal of Hepatology
Journal of Hepatology, 2012, 57 (3), pp.564-71. ⟨10.1016/j.jhep.2012.04.022⟩
Journal of Hepatology, Elsevier, 2012, 57 (3), pp.564-71. ⟨10.1016/j.jhep.2012.04.022⟩

International audience; BACKGROUND & AIMS: We aimed at determining the effect of maintenance therapy with ribavirin alone, after a year of combined peginterferon-alfa 2a (PegIFNα-2a) and ribavirin therapy, on viral response and liver histology after

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8384f0a40dadee44e9270fadb1a3a759
https://hal.science/hal-00865405

From Atherosclerotic Plaque to Myocardial Infarction—The Leading Cause of Coronary Artery Occlusion.

Autor: Młynarska, Ewelina¹ (AUTHOR) emmlynarska@gmail.com, Czarnik, Witold¹ (AUTHOR), Fularski, Piotr¹ (AUTHOR), Hajdys, Joanna¹ (AUTHOR), Majchrowicz, Gabriela¹ (AUTHOR), Stabrawa, Magdalena¹ (AUTHOR), Rysz, Jacek² (AUTHOR), Franczyk, Beata¹ (AUTHOR)

Publikováno v: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 13, p7295. 27p.

[Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences]

Autor: F, Roudot-Thoraval, A, Abergel, F, Allaert, M, Bourlière, H, Desmorat, F, Fagnani, T, Fontanges, A, Hanana, S, Pol, J P, Zarski, C, Rousseaux, C, Gandossi, L, Samelson, S, Dole, S, Dantin, F, Eberlé, M F, Saint-Marc-Girardin, L, Abelsour

Publikováno v: Gastroenterologie clinique et biologique. 25(12)

The aim of this observational study in patients with chronic hepatitis C and treated with interferon alpha-2a was to assess 1) monitoring in everyday practice, 2) the acceptability of treatment and 3) the intensity of fatigue.Three hundred and fifty

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3fa0a20c9bffaf8cf9f0fce75737768e
https://pubmed.ncbi.nlm.nih.gov/11910986